Ente Ecclesiastico Ospedale Generale Regionale Miulli

The medical center is at the forefront of nephrology research, focusing on innovative therapies for Idiopathic IgA nephropathy (IgAN). The center's research aims to enhance treatment protocols by evaluating the effects of targeted therapies based on kidney biopsy findings.

• Targeted therapy for IgAN
• Early corticosteroid intervention
• Combination therapies with SGLT2 inhibitors

By exploring the therapeutic impact of early corticosteroid therapy and SGLT2 inhibitors, the center contributes to reducing proteinuria and minimizing potential side effects, thus advancing patient care in nephrology.

Specializing in oncology, the center conducts pivotal studies on advanced non-small cell lung cancer and pleural mesothelioma. The research focuses on the efficacy of novel drug combinations in patients with specific genetic markers.

• Niraparib and dostarlimab combination therapy
• PD-L1 expression and HRR gene mutations
• Progression-free survival evaluation

Through these studies, the center aims to improve progression-free survival rates, offering new hope for patients with challenging cancer types by tailoring treatments to genetic profiles.

The center is a leader in gynecologic oncology, focusing on BRCA wild-type advanced ovarian, fallopian tube, and primitive peritoneal cancer. Research efforts are directed towards understanding the efficacy of maintenance therapies in newly diagnosed cases.

• Olaparib maintenance therapy
• Prognostic value of clinical and biological characteristics
• Tumor biomarker evaluation

By investigating the role of Olaparib and analyzing tumor biomarkers, the center seeks to enhance treatment outcomes and provide personalized therapeutic strategies for patients.